Dynamic quotes: Off
|
Company Description (as filed with the SEC)
DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries. Ambulatory Product Line: SEVEN® PLUS, G4® and DexCom G4 PLATINUM® We received approval from the Food and Drug Administration (“FDA”) and commercialized our first product in 2006. In 2007, we received approval and began commercializing our second generation system, the SEVEN. We no longer market or provide support for the SEVEN system. In 2009 we received approval for our third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use, and we began commercializing this product in the first quarter of 2009. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.81 |
| Quarterly EPS Est: | -0.16 |
| PEG Ratio: | -1.11 |
|
Mean Recommendation: View Summary / View All |
1.85 |
Data is provided by Zacks Investment Research


